Recurrent Pleural Effusion Management

Primary Causes and Initial Management

Malignancy is the most common cause of recurrent pleural effusion requiring intervention, followed by heart failure and other transudative causes, according to the American Thoracic Society 1
The American College of Chest Physicians recommends that lung cancer, breast cancer, lymphoma, and ovarian cancer are the most frequent malignancies causing recurrent pleural effusions 1
Small cell lung cancer, lymphoma, and breast cancer may respond to systemic chemotherapy, though effusions often still require local intervention during treatment, as suggested by the National Comprehensive Cancer Network 1

The European Respiratory Society recommends observation alone for asymptomatic pleural effusions, regardless of size, with close monitoring as most patients eventually become symptomatic and require intervention 1, 2
For all new symptomatic effusions, the American Thoracic Society suggests performing ultrasound-guided thoracentesis removing ≤1.5L to assess symptom relief and determine transudative vs exudative etiology 4
The critical pitfall of never removing >1.5L in a single session due to risk of re-expansion pulmonary edema is emphasized by the British Thoracic Society 4, 2, 6, 3

The American Heart Association recommends directing treatment toward the underlying medical condition first for transudative effusions, such as heart failure, cirrhosis, and nephrosis 4, 2
Maximize cardiac therapy including diuretics and SGLT2 inhibitors before considering pleural interventions, as suggested by the European Society of Cardiology 3
For refractory symptomatic effusions despite optimal medical therapy, repeated therapeutic thoracentesis (≤1.5L per session) is first-line for patients with very short life expectancy, according to the American Academy of Hospice and Palliative Medicine 1, 2, 6, 3

The National Comprehensive Cancer Network recommends that either indwelling pleural catheter or chemical pleurodesis should be used as first-line definitive treatment for symptomatic malignant effusions with expandable lung, as both are equally effective 2
Talc pleurodesis achieves 93% success rate and is the most effective sclerosant, as reported by the American Thoracic Society 4, 6
Indwelling pleural catheter reduces hospitalization and is preferred when minimizing hospital stay is priority, according to the Society of Thoracic Surgeons 7, 6

The Infectious Diseases Society of America recommends hospitalizing all patients and initiating IV antibiotics covering common respiratory pathogens for parapneumonic effusion/empyema 2
Insert small-bore chest tube (≤14F) for drainage if pH <7.2 or glucose <3.3 mmol/L, as suggested by the American Thoracic Society 2

The American Society of Clinical Oncology recommends suspending treatment or reducing dose, with or without steroids and diuretics, for drug-induced pleural effusions, such as those caused by dasatinib 5
For grade 3-4 effusions, thoracentesis may be necessary, according to the National Comprehensive Cancer Network 5

Never attempt pleurodesis without confirming complete lung expansion on post-drainage imaging, as this will fail in trapped lung, as emphasized by the American Thoracic Society 2, 6
Do not delay systemic chemotherapy in favor of local pleural treatment alone for chemotherapy-responsive malignancies, according to the National Comprehensive Cancer Network 2